Press Release
RainDance Technologies and CLC bio Collaborate to Develop Specialized Software Solutions for Targeted Resequencing
Lexington, Massachusetts, U.S.A., and Aarhus, Denmark – September 17, 2009 – RainDance Technologies and CLC bio today announced a partnership to develop specialized software for the analysis of targeted resequencing data generated by workflows incorporating RainDance’s Sequence Enrichment Solution and next-generation DNA sequencing platforms.
“The rapid and efficient analysis of genomic data plays an important role in searching for the variants in large populations that cause cancer and other devastating diseases,” said Christopher McNary, President and Chief Executive Officer, RainDance Technologies. “By partnering with CLC bio, we can supply researchers with a solution that leverages the power of our innovative microdroplet-based technology to provide the highest-quality results in a simple yet powerful workflow. This capability will help accelerate the advent of personalized medicine and make profound contributions to health and human disease research,” he said.
CLC bio’s Chief Executive Officer, Thomas Knudsen, continues, "Having decided to focus on high-throughput sequencing technologies several years ago, we're constantly monitoring the market to identify new and complementary technologies being developed. The sequence enrichment platform from RainDance Technologies is truly innovative, and we are very much looking forward to making it even more valuable in supporting the full scientific workflow of their customers. We are proud to partner with RainDance on helping global science gain new ground.”
As a first step, CLC bio will release an expansion of its CLC Genomics Workbench, enabling scientists to analyze data faster and more effectively when using the RainDance solution for large-scale targeted resequencing studies. The software is already in use by RainDance scientists and will be released for commercial sale later this month.
The CLC bio/RainDance solution can be used with any next-generation sequencing workflow, giving customers the freedom to choose between the Illumina Genome Analyzer, Roche 454, or ABI SOLiD systems.
In the future, the partnership will continue to release specialized reports, data analyses, and workflow support for platform-independent targeted resequencing research that will provide additional value to RainDance customers.
To read more about CLC bio’s customized solutions, go to: http://www.clcbio.com/index.php?id=485
About RainDance Technologies, Inc.
RainDance's proprietary technology platform delivers exquisite sensitivity and data quality that inspires scientists, researchers and clinicians to rethink the way they design experiments, approach discovery, or conduct clinical diagnostics. The core RainStorm™ technology empowers customers to conduct de novo science in an ultra-high throughput, simple, flexible, and low-cost manner. RainDance's commercial products include instruments and high-value consumables and reagents for sequence enrichment for next-generation sequencing, ultra-deep sequencing, and methylation analysis. RainDance sells directly in the U.S. and in Europe, and is building distribution networks in Europe and Asia-Pacific. RainDance Technologies has approximately 70 employees worldwide. For more information, please visit www.raindancetech.com.
RainStorm is a trademark of RainDance Technologies, Inc.
About CLC bio
For corporate questions contact:
Chris McNary
RainDance Technologies
44 Hartwell Avenue
Lexington, MA 02421
Phone — 781-861-6300
mcnaryc@raindancetech.com
For technical questions contact:
James Brayer
RainDance Technologies
44 Hartwell Avenue
Lexington, MA 02421
Phone — 781-861-6300
info@raindancetech.com
For press inquiries:
Colin Sanford
Phone — 203-340-2441
colin@bioscribe.com
